Skip to main content
BTMD
NASDAQ Life Sciences

Biote Swings to Q2 Loss, Slashes Full-Year Outlook as Recall Fallout Persists

Arie Shkolnikov · Analysis by Wiseek AI
More coverage: Healthcare Facility Stocks · Healthcare
Sentiment info
Negative
Importance info
8
Price
$1.97
Mkt Cap
$84.934M
52W Low
$1.27
52W High
$4.2
52W Position info
55% above low
Off High info
53% below high
Rel. Volume info
0.3× avg
Market data snapshot near publication time

BTMD sits 55% above its 52-week low of $1.27 on light trading volume (0.3× avg).

Summary

Biote posted a Q2 net loss of $7.4M on revenue of $44.2M, down 9.5% year-over-year, and slashed its full-year outlook as the voluntary product recall continues to hurt procedure revenue and margins.


Key Events · Earnings and Guidance · BTMD

  • Q2 Revenue Falls 9.5%

    Total revenue of $44.2M, down from $48.9M in Q2 2025, driven by a 13.9% decline in procedure revenue to $30.3M due to the ongoing voluntary pellet recall.

  • Swings to Net Loss

    Net loss of $(7.4)M, or $(0.23) per share, compared to net income of $3.9M, or $0.10 per share, in the prior-year quarter. Operating loss was $(3.5)M versus income of $10.8M.

  • Adjusted EBITDA Plunges

    Adjusted EBITDA fell to $5.6M (12.6% margin) from $15.2M (31.1% margin), reflecting lower revenue, reduced gross margin (65.4% vs. 71.6%), and higher operating expenses.

  • Full-Year Guidance Slashed

    Management now expects 2026 revenue above $175M and Adjusted EBITDA above $25M, a significant reduction from prior expectations, with procedure revenue still negative year-over-year in H2.


Analysis · BTMD · Life Sciences

A sharp reversal from profit to loss in Q2 2026 underscores deepening strain at Biote. Revenue fell 9.5% and Adjusted EBITDA collapsed to $5.6M from $15.2M a year ago, as the voluntary pellet recall continued to weigh on procedure revenue and margins. Management responded by slashing full-year guidance, now calling for revenue above $175M and Adjusted EBITDA above $25M—a significant downgrade from the trajectory implied by prior commentary. With cash down to $11.2M from $24.1M at year-end and a recent CEO departure, the results highlight mounting operational and financial pressure.

At the time of this filing, BTMD was trading at $1.97 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $84.9M. The 52-week trading range was $1.27 to $4.20. This filing was assessed with negative market sentiment and an importance score of 8 out of 10.

View Main SEC Filing

Price Chart

Share this article

Copied!

BTMD - Latest Insights

BTMD
Jun 17, 2026, 4:05 PM EDT
Filing Type: 8-K/A
Importance Score:
7
Price at Filing: $2.27
Real-time Price: $2.12 info
Change: -$0.1488 (-7%) info
Market Cap: $84.934M info
BTMD
Jun 02, 2026, 5:17 PM EDT
Filing Type: 8-K
Importance Score:
8
Price at Filing: $2.15
Real-time Price: $2.12 info
Change: -$0.0288 (-1%) info
Market Cap: $84.934M info
BTMD
May 11, 2026, 4:11 PM EDT
Filing Type: 10-Q
Importance Score:
9
Price at Filing: $2.21
Real-time Price: $2.12 info
Change: -$0.0888 (-4%) info
Market Cap: $84.934M info
BTMD
May 06, 2026, 4:10 PM EDT
Filing Type: 8-K
Importance Score:
8
Price at Filing: $2.14
Real-time Price: $2.12 info
Change: -$0.0188 (-0.88%) info
Market Cap: $84.934M info
BTMD
Apr 03, 2026, 4:10 PM EDT
Filing Type: 8-K
Importance Score:
8
Price at Filing: $1.59
Real-time Price: $2.12 info
Change: +$0.5312 (+33%) info
Market Cap: $84.934M info